Cigna Corp. Stock
Price
Target price
€255.60
€255.60
1.190%
3.0
1.190%
€289.34
09.06.26 / Tradegate
WKN: A2PA9L / Symbol: CI / Name: Cigna / Stock / Healthcare Providers & Services / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cigna Corp. Stock
There is an upward development for Cigna Corp. compared to yesterday, with an increase of €3.00 (1.190%).
With 34 Buy predictions and not a single Sell prediction Cigna Corp. is an absolute favorite of our community.
As a result the target price of 289 € shows a slightly positive potential of 13.07% compared to the current price of 255.6 € for Cigna Corp..
Pros and Cons of Cigna Corp. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cigna Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cigna Corp. | 1.190% | 8.998% | 4.540% | -6.494% | 8.998% | 3.273% | 28.571% |
| Centene Corp. | 1.810% | 11.206% | 20.758% | 17.505% | 65.900% | -10.724% | -2.780% |
| Humana Inc. | 0.650% | 14.493% | 35.043% | 54.674% | 43.898% | -33.850% | -8.907% |
| UnitedHealth Group Inc. | 1.250% | 10.092% | 10.980% | 35.376% | 27.695% | -22.133% | 8.638% |
Comments
Cigna Group (CI) had its price target raised by Mizuho from $330.00 to $340.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CI provided by MarketBeat
Cigna Group (CI) had its price target lowered by Piper Sandler from $370.00 to $346.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CI provided by MarketBeat
Cigna Group (CI) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for CI provided by MarketBeat
News
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage
Key Points
- Interested in Eli Lilly and Company? Here are five stocks we like better.
- After CVS made Novo Nordisk its preferred GLP-1 provider in 2025, Lilly shares took a huge hit.
- However, CVS
Progyny Q1 Earnings Call Highlights
Progyny (NASDAQ:PGNY) reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and